Welcome to our dedicated page for Illumina news (Ticker: $ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Illumina's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Illumina's position in the market.
Illumina reported financial results for Q1 2024, with core revenue at $1.06 billion, a 2% decrease from Q1 2023. GAAP operating margin was 11.0% and non-GAAP operating margin was 20.6%. Revenue decreased by 1% to $1.08 billion. GAAP diluted loss per share was ($0.79), while non-GAAP diluted earnings per share were $0.09. Illumina aims to divest GRAIL by end of Q2 2024, with a funding commitment of $1 billion in a capital markets transaction.
In celebration of DNA Day, Illumina in Cambridge, United Kingdom, hosted 150 students for hands-on science activities, inspiring young scientists to pursue careers in STEM. HRH The Princess Royal visited the event, emphasizing the importance of genomics and STEM education. The Future Is Bright initiative, promoting global genomic literacy, engages 100,000 learners annually, aiming to reach 5 million by 2030.